Genmab — Maj 2015
-
@Solsen vedr TF safety for 2.0 mg. Jeg kender ikke noget til statistik ifm evaluering af safety i klinik, kun statistik generelt, og jeg troede det ville være muligt at interpolere mellem 1.8 og 2.2 mg evt suppleret med evaluering af fx 2.0 mg i en begrænset gruppe pts, men den går åbenbart ikke
-
-
Ok..Tak Royal. Jeg havde haft en mega travl dag i går. Faldt ufriviligt søvn kl. 21.
-
Der er kommet agenda for J&J dagen nu: http://www.investor.jnj.com/webcasts-presentations.cfm
-
Peter Lebowitz gennemgår oncology 1 pm. så nok der vi skal være obs
-
"Janssen oncology is poised for another strong showing at ASCO this year, showcasing our continued strides to make a difference in the lives of people living with cancer," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen. "Of the five Janssen compounds being featured, we are particularly excited about new daratumumab monotherapy data in multiple myeloma
-
Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
/PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data from five oncology treatments across the portfolio, including marketed and...
(www.prnewswire.com)
-
God morgen.
-
Lyt med på Millionærklubben i dag. Jeg snakker biotek - og selvfølgelig også Genmab.
-
Det kommer senere i dag.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind